Get the Stockscreener App
9.05
0.98%
-0.09
After Hours:
9.04
-0.01
-0.11%
Kura Oncology Inc stock is traded at $9.05, with a volume of 874.19K.
It is down -0.98% in the last 24 hours and up +4.62% over the past month.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
See More
Previous Close:
$9.14
Open:
$9.23
24h Volume:
874.19K
Relative Volume:
0.60
Market Cap:
$803.30M
Revenue:
$67.48M
Net Income/Loss:
$-278.67M
P/E Ratio:
-2.8482
EPS:
-3.1774
Net Cash Flow:
$-70.70M
1W Performance:
+2.96%
1M Performance:
+4.62%
6M Performance:
-12.05%
1Y Performance:
+50.08%
1-Day Range:
$8.895
$9.279
1-Week Range:
$8.58
$9.279
52-Week Range:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.05 | 811.29M | 67.48M | -278.67M | -70.70M | -3.1774 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
KURA Initiates Coverage On Lake Street -- Price Target Announced at $23 - GuruFocus
Aug Drivers: What are the future prospects of Kura Oncology IncMarket Growth Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
[ARS] Kura Oncology, Inc. SEC Filing - Stock Titan
Kura Oncology (NASDAQ: KURA) plans votes on pay, equity plan and auditor - Stock Titan
Bond Watch: Why is Kura Oncology Inc stock going up2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura to unveil new kidney cancer combo data in previously treated patients - Stock Titan
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 - Bitget
Breakout Move: Is Kura Oncology Inc vulnerable to short sellers2026 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule - National Today
Kura Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan - Quiver Quantitative
Cancer drugmaker Kura gives 6 new hires options on 153,750 shares - Stock Titan
Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Kura Oncology: Commercialization In AML Presents Asymmetric Upside (NASDAQ:KURA) - Seeking Alpha
Vanguard reports 0% ownership in Kura Oncology (NASDAQ: KURA) - Stock Titan
Kura Oncology Inc (HAM:KUR) Stock Price, Trades & News - GuruFocus
Kura Oncology (NASDAQ: KURA) CEO exercises options, increases share stake - Stock Titan
Mizuho Cuts Price Target on Kura Oncology to $25 From $30, Keeps Outperform Rating - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00 - MarketBeat
Mizuho cuts Kura Oncology stock price target on delayed sales By Investing.com - Investing.com Canada
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Kura Oncology Inc stock surges on positive mid-stage trial results for key cancer drug candidate - AD HOC NEWS
KURA SEC FilingsKura Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Is Kura Oncology Inc a strong candidate for buy and holdMarket Sentiment Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Kura Oncology (KURA) director exercises 10,000 options for shares - Stock Titan
Kura Oncology Inc Stock (ISIN: US50126D1028) Faces Post-Earnings Pressure Amid Komzifti Launch Chall - AD HOC NEWS
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance - MSN
UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15 - Meyka
Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA - MarketBeat
KURA: UBS Analyst Maintains 'Buy' Rating But Lowers Price Target | KURA Stock News - GuruFocus
UBS lowers Kura Oncology stock price target to $15 on launch data - Investing.com Canada
Implied volatility surging for Kura Oncology stock options - MSN
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - TradingView
KURA: Komzifti and ziftomenib advance with strong launch, global trials, and promising pipeline updates - TradingView — Track All Markets
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
UBS Reaffirms Their Buy Rating on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kura Oncology Inc Stock (KURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malley Thomas | Director |
Mar 18 '26 |
Option Exercise |
3.12 |
10,000 |
31,200 |
10,000 |
| Powl Brian T. | Chief Commercial Officer |
Jan 27 '26 |
Sale |
8.46 |
6,414 |
54,266 |
183,275 |
| FORD KATHLEEN | Chief Operating Officer |
Jan 27 '26 |
Sale |
8.46 |
1,813 |
15,339 |
153,560 |
| Leoni Mollie | Chief Medical Officer |
Jan 27 '26 |
Sale |
8.46 |
8,180 |
69,209 |
267,274 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting |
Jan 27 '26 |
Sale |
8.46 |
7,142 |
60,426 |
145,167 |
| Burrows Francis | Chief Scientific Officer |
Jan 27 '26 |
Sale |
8.46 |
1,311 |
11,092 |
32,424 |
| Bair Teresa Brophy | Chief Legal Officer |
Jan 27 '26 |
Sale |
8.46 |
11,208 |
94,828 |
226,931 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):